Group 1 - Southbound funds increased their holdings in Alibaba Health (00241.HK) by 3.354 million shares on November 26, 2025, marking a 0.19% change [1][2] - Over the past five trading days, southbound funds have increased their holdings for four days, with a total net increase of 6.738 million shares [1] - In the last 20 trading days, there have been 13 days of net increases, totaling 44.136 million shares [1] Group 2 - As of now, southbound funds hold 1.784 billion shares of Alibaba Health, accounting for 11.02% of the company's total issued ordinary shares [1] - The company primarily engages in the sale of pharmaceutical health products and operates e-commerce platforms for pharmaceuticals and consumer healthcare services [2] - Alibaba Health is a flagship platform for Alibaba Group in the health sector, utilizing cloud computing and big data technologies for digital healthcare and internet medical services [2]

Core Insights - Alibaba Health reported a total revenue of 16.697 billion RMB for the six months ending September 30, 2025, representing a year-on-year growth of 17.0% [1] - The net profit reached 1.266 billion RMB, showing a significant increase of 64.7% compared to the previous year, with a net profit margin rising from 5.4% to 7.6% [1] - Adjusted net profit was 1.356 billion RMB, reflecting a year-on-year growth of 38.7% [1] Group 1: Business Performance - The Tmall Health platform maintained continuous growth in annual active consumers, with a stable increase in gross merchandise volume over the past six months [1] - The number of online products increased by over 24% to more than 97 million stock-keeping units, while the number of service merchants grew by over 39% to exceed 56,000 [1] - Self-operated business revenue reached 14.380 billion RMB, marking an 18.6% year-on-year increase, with prescription drugs and original research drugs categories experiencing rapid growth [1][2] Group 2: Strategic Initiatives - The company capitalized on supply-side structural optimization opportunities in the healthcare product categories, continuously enhancing the operational efficiency of its self-operated business [2] - Alibaba Health is deepening partnerships with pharmaceutical companies, actively introducing leading brands, and expanding collaboration channels to further enhance user perception [2] - The company is upgrading its healthcare service experience, providing integrated online and offline medical services across multiple platforms, including traditional Chinese medicine, health checks, diagnostics, consultations, appointments, vaccinations, dental care, psychological services, vision care, and nursing [2]

本报讯 （记者袁传玺）11月26日，阿里健康发布2026财年中期业绩公告。截至2025年9月30日的6个月 内，阿里健康营收达166.97亿元，同比增长17%；毛利达41.84亿元，同比增长18.4%；净利润达12.66亿 元，同比增长64.7%；经调整后净利润为13.56亿元，同比增长38.7%。公司业务增长稳健、高质量发展 态势巩固。同时，阿里健康将持续投入医疗AI领域，不断深化在toB医疗垂类领域的战略布局，加速医 疗AI领域的深耕与突破。 公告显示，作为国内年度活跃用户数最高和年度商品交易总额最大的线上B2C医疗健康品零售平台，阿 里健康围绕用户日益增长的健康需求，不断提升供给侧产品丰富度、优化用户体验。截至2025年9月30 日，天猫健康平台服务商家数超5.6万家，SKUs增长超9700万个，年度活跃用户数及年化ARPU持续保 持增长，平台GMV实现同比高质量稳定增长。阿里健康大药房持续提升自营业务的运营效率，自营盈 利能力显著提升。报告期内，业务收入达143.8亿元，同比增长18.6%；年度活跃用户数与会员ARPU持 续增长，SKU同比增长98.8%至161万。 作为新特药首发阵地，阿里健康持续深 ...

在痛风防治领域，双方将共同探索构建覆盖尿酸监测、用药管理及长期随访的数字化防治体系；在呼吸 与过敏领域，依托专业管线产品，聚焦于构建从预防、诊断到治疗与康复的线上支持体系，让专业健康 服务更加可及；在营养补充领域，双方将整合研发与渠道优势，最终旨在为各年龄段人群提供精准营养 与体重管理解决方案等。 据介绍，随着本次战略合作的达成，金赛药业全球首款长效痛风药物"金蓓欣"伏欣奇拜单抗将在京东健 康开启预约。 此前在11月13日晚间，京东健康发布的2025年第三季度业绩报告显示，期内实现收入171.2亿元，同比 增长28.7%；非国际财务报告准则指标下(Non-IFRS)净利润为19亿元，同比增长42.4%。报告期内，京东 健康全网首发超30款新特药，持续巩固"新特药全网首发第一站"优势。 11月26日，京东健康与金赛药业签署战略合作协议。双方将聚焦儿童健康、痛风、呼吸与过敏、女性健 康、营养补充等六大领域，打造以患者为中心的疾病全周期健康管理解决方案。 官网显示，金赛药业是一家创新驱动的全产业链制药企业。作为长春高新（000661）控股子公司，金赛 药业拥有完整的研产销全产业链体系，年营收超百亿元，已推出核心产品 ...

此外，阿里健康与礼来、阿斯利康、欧加隆、拜耳、辉瑞、诺和诺德、罗氏等头部企业达成战略合作， 在线上零售、品类拓展、新药首发、疾病教育等领域，全面展开数字化健康服务合作，帮助药企伙伴拓 展院外市场。 报告期内，阿里健康持续为用户提供线上线下一体化的医疗健康服务。与阿里健康签约提供在线健康咨 询服务的执业医师、执业药师和营养师合计超25万人，较去年同期增加2万余人。截至2025年9月30日止 6个月内，自营慢病业务的用户数量及其ARPU均实现持续增长。 责任编辑：何俊熹 新浪科技讯 11月26日晚间消息，阿里健康发布2026财年中期业绩公告。截至2025年9月30日止六个月 内，阿里健康营收达人民币166.97亿元，同比增长17%；毛利达41.84亿元，同比增长18.4% ；净利润达 12.66亿元，同比增长达64.7%；经调整后净利润为13.56亿元，同比增长38.7%。 公告显示，截至2025年9月30日，天猫健康平台服务商家数超5.6万家，SKUs增长超9700万个，年度活 跃用户数及年化ARPU持续保持增长，平台GMV实现同比高质量稳定增长。阿里健康大药房持续提升自 营业务的运营效率，自营盈利能力显著提升 ...

Core Insights - Alibaba Health (00241) reported a total revenue of 16.697 billion RMB for the six months ending September 30, 2025, representing a year-on-year growth of 17.0% [1] - The net profit reached 1.266 billion RMB, showing a significant increase of 64.7%, with the net profit margin rising from 5.4% to 7.6% [1] - Adjusted net profit was 1.356 billion RMB, reflecting a year-on-year growth of 38.7% [1] Revenue and Profitability - The company's self-operated business generated revenue of 14.38 billion RMB, marking an 18.6% year-on-year increase [1] - The annual active user count and average revenue per user (ARPU) for the self-operated business continued to grow [1] Platform Performance - The Tmall Health platform maintained a steady increase in annual active consumers, with the gross merchandise volume (GMV) showing high-quality stable growth over the past six months [1] - The company is enhancing operational efficiency in its self-operated business by seizing opportunities in the supply-side structural optimization of healthcare products [1] AI Investment - The company is continuously investing in the medical AI sector, focusing on deepening its AI applications and tools in the B2B medical vertical [2] - This initiative aims to meet the growing AI demands of the healthcare industry and physicians, promoting high-quality business development [2]

董事会预期截至2027年3月31日止两个财政年度的营销推广服务之原有年度上限将不足以满足集团的业 务需要。因此，于2025年11月26日，董事会建议按照上市规则第14A章的规定修订截至2027年3月31日 止两个财政年度的营销推广服务之原有年度上限。 格隆汇11月26日丨阿里健康(00241.HK)公告，内容有关（其中包括）公司与阿里妈妈就提供营销推广服 务而订立的2025年至2027年营销推广服务框架协议，为期三(3)年，自2024年4月1日起至2027年3月31日 止，除非根据其条款另行终止。 ...

Group 1 - Alibaba Health (00241) shares increased by nearly 3%, currently trading at 6.1 HKD with a transaction volume of 499 million HKD [1] - There is a significant rise in demand for flu-related medications on Alibaba Health's platform, with a more than 500% week-on-week increase in the number of buyers for antiviral drugs [1] - The drug Mabalosavir showed exceptional performance, with a more than 600% increase in the number of buyers compared to the previous week [1] Group 2 - The flu season has started earlier this year, with a rapid increase in flu activity nationwide, particularly in Beijing, which has entered a high incidence period for respiratory infectious diseases [1] - According to Everbright Securities, the demand for cold medications is expected to exceed market expectations in Q4 2025, as flu cases rise with the drop in temperatures [1] - The recent increase in flu cases is likely to raise public and market awareness, driving demand for flu prevention and testing products [1]

Core Viewpoint - Alibaba Health (00241) has seen a nearly 3% increase in stock price, attributed to a significant rise in demand for flu-related medications on its platform as the flu season approaches [1] Group 1: Stock Performance - Alibaba Health's stock price rose by 2.01%, reaching 6.1 HKD, with a trading volume of 499 million HKD [1] Group 2: Demand for Flu Medications - There has been a notable increase in the demand for flu medications on Alibaba Health's platform, with a more than 500% week-on-week growth in the number of buyers for antiviral drugs [1] - Specifically, the drug Mabalosavir has seen a remarkable increase, with buyer numbers growing over 600% week-on-week, leading the growth [1] - Oral antiviral liquid medications also experienced a 50% week-on-week increase in buyer numbers, indicating heightened consumer awareness regarding flu prevention and treatment [1] Group 3: Market Trends and Projections - According to reports, flu activity has rapidly increased nationwide since November, with Beijing entering a high incidence period for respiratory infectious diseases [1] - Everbright Securities forecasts that as temperatures drop, flu cases will rise significantly, potentially increasing public and market attention on flu prevention and testing products [1] - The demand for cold medications is expected to peak in Q4 2025, with sales and shipments likely to see a turnaround, surpassing market expectations due to the current upward trend in flu cases [1]

Core Insights - The core theme of the conference was "Collaborative Win-Win: Smartly Leading the Future," focusing on enhancing chronic disease management through artificial intelligence [1][2] - The strategic partnership between Fangzhou Jianke and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. aims to explore innovative approaches in the health industry empowered by AI [1][6] Industry Trends - The National Health Commission issued guidelines promoting the application of AI in healthcare, outlining core goals and pathways for the next five years [2] - The aging population and the increasing prevalence of chronic diseases in younger demographics highlight the critical role of AI technology in healthcare [2] Company Developments - Fangzhou Jianke's CEO, Dr. Xie Fangmin, emphasized the importance of addressing real problems and driving genuine change in chronic disease management through AI [2][4] - The user engagement with the "AI Health Steward" platform has significantly increased, with user numbers in October being 2.4 times that of September and GMV rising by 50% [4] Strategic Collaborations - The partnership with Wangshan Wangshui is designed to integrate technological empowerment with product pipeline advantages, aiming for a comprehensive upgrade from drug supply to health services [6][8] - Both companies plan to create replicable and scalable AI-driven solutions for chronic disease management, enhancing the quality of development in the health industry [5][6]